Articles tagged with Personalized Medicine
The Mount Sinai Hospital is launching the first-ever genetic testing program in primary care settings to identify genetic risk for kidney disease in patients with hypertension. This $3.7 million grant will provide genomic information to individualize treatment, testing, and monitoring, with a focus on African Americans who are four to ...
Research by Northwestern Medicine cardiologist Jeffrey Goldberger combines evidence-based guidelines with tailored treatment for patients, reducing over-treatment and under-treatment. By analyzing clinical data and individual characteristics, physicians can make more precise decisions, leading to better patient care.
A recent study found that vaginal microbes change in some healthy women over short periods, while remaining stable in others. These changes can impact a woman's susceptibility to infections and diseases. Researchers hope this research will lead to personalized medicine for women.
The Canadian Institutes of Health Research will lead a landmark research competition to develop personalized treatments for various diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. The investment aims to transform the delivery of healthcare through predictive, preventive, and precision care.
Researchers propose using personalized medicine to identify individuals at highest risk for developing type 2 diabetes, allowing for targeted prevention efforts. Current methods are inefficient, but new biomarkers and approaches hold promise for preventing and controlling the disease.
A new study found that more than 85% of US states have inadequate genetics standards for preparing high school students for personalized medicine. The study, published by the American Society of Human Genetics, rates only seven states as 'adequate' in genetic literacy.
The American Chemical Society honors Keith H. Gibson, Andrew J. Barker, and George L. Trainor for their contributions to personalized medicine and genetic sequencing. The trio developed a new drug that helped pioneer the era of 'personalized medicine' for cancer patients.
Despite genomics' promise in treating cancer and cardiovascular disease, personalized medicine's complexities limit tailored interventions. The authors advocate for a more holistic approach focusing on the person as a whole, rather than abstract scientific manipulations.
The Research Institute of the McGill University Health Centre (RI-MUHC) has been awarded a $1.4M grant to develop Personalized Medicine for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH). The project aims to identify new biomarkers and disease predictors to improve diagnosis and treatment options.
A recent study published in PLOS ONE found that ancestral genetic heritage is not fixed at the individual level for African-American and Hispanic patients, but rather varies widely within each group. This research challenges traditional ethnic labels and highlights the importance of considering individual genotypes in personalized medi...
This special issue of Perspectives on Psychological Science investigates the potential of genetics research, personalized medicine, and behavioral intervention to improve patient care. The articles examine the intersection of behavior and genetics, with a focus on tailoring treatments to individual genetic characteristics.
A series of essays examines the challenges in determining effective treatments, benefits and drawbacks for patients, as well as consumers' right to their genetic information. The articles discuss controversies surrounding direct-to-consumer tests, genetically customized drug treatments and biospecimen use.
This special edition of The Hastings Center Report examines the promise and pitfalls of personalized medicine, from direct-to-consumer genetic testing to hospice care. Key findings include the need for thousands of human biospecimens for genetic studies, as well as debates over individual mandates in healthcare reform.
Experts in pathology are advocating for a comprehensive training program to integrate genomics and personalized medicine into daily practices. The proposed curriculum would cover laboratory medicine, genetic counseling, and health information technology, enabling pathologists to serve as primary consultants for physicians and patients.
A model predicting warfarin doses based on genetic information and clinical factors shows improved results, particularly for patients at high risk of bleeding or clotting. The study suggests personalized medicine holds promise in optimizing medication treatment.
Canada has a unique opportunity to become an international leader in personalized medicine, driven by advancements in human genome sequencing and genetic research. The country can capitalize on its strengths to provide a model for other nations.
A $12.5 million grant from Charles Bronfman will establish the Charles Bronfman Institute for Personalized Medicine, transforming medical practice with genomics-based strategies for disease detection and treatment. The gift will seed a $30 million initiative to advance personalized medicine at Mount Sinai.
As pharmacogenomics adoption advances, physicians are at risk of lawsuits for not recommending genetic tests before prescribing drugs that may harm patients with genetic vulnerabilities. Experts predict an increase in liability risks, citing scientific uncertainty, social concerns, and economic costs as hurdles.
Mount Sinai Journal of Medicine will transition to Wiley, focusing on translational and personalized medicine, featuring articles on clinical care, bio-medical research, and patient outcomes. The journal's redesign aims to bridge the gap between scientific discovery and clinical application.
A new system, Genomic Messaging System (GMS), has been developed to store and transmit whole sequences of patient DNA in a compressed form while maintaining privacy. This technology could enable doctors to prescribe tailored treatments based on unique genetic variations.